EYP001



NAME OF DRUG : EYP001

LABORATORY : ENYOPHARMA

STATUS AND ADVANCEMENT

Type of drug : Non BA FXR agonist

Clinical trials advancement : Analysing Results Phase 2a

Estimated time to market : 114 months.

LABORATORY ABSTRACT ON THE DRUG

EYP001 which is an orally bioavailable synthetic non-steroidal, non-bile acid FXR agonist small molecule is also developed in NASH. Most Key Opinion Leaders agree that FXR agonists could become the backbone of any future NASH therapies. It has demonstrated its efficacy in a Stelic mouse model (STAMTM) with significant positive impact on most of the NASH key parameters (Fibrosis, Steatosis, Inflammation, Ballooning, triglycerides and NAS). It differentiates from other FXR agonists by a better C4/FGF19 balance with a more prolonged C4 decrease and a lower peak of FGF19 expected to generate a better efficacy/tolerability profile.

RECENT NEWS ON EYP001

SOME PUBLICATIONS RELATED WITH EYP001

SOME NASHBIOTECHS POINTS OF VIEW RELATED WITH EYP001


WWW.NASHBIOTECHS.COM  -  Copyright G DIVRY 2015-2016  - Contact and TERMS OF USE